
Worldwide trends in diabetes prevalence and treatment from 1990 to 2022

NCD Risk Factor Collaboration (NCD-RisC) www.ncdrisc.org




A global study by a global collaboration

- Nearly 1,000 global collaborators; coordinated via WHO Collaborating Centre on NCD Surveillance, Epidemiology and Modelling
- Data from 1,108 population-based studies with 141 million participants in 175 countries, and with measurement of diabetes biomarkers






Over 800 million adults lived with diabetes in 2022




Nearly 450 million were not treated for their diabetes






Prevalence of diabetes has increased in most countries, especially in low- and middle-income countries

2022






Rates of treatment have improved unevenly across the world, stagnating in many low- and middle-income countries








Substantial inequality in contemporary treatment coverage





The majority of people with untreated diabetes live in low- and middle-income countries





Summary

- In most countries, especially in low- and middle-income countries, diabetes treatment has not increased at all or has not increased sufficiently in comparison with the rise in prevalence.
- The burden of diabetes and untreated diabetes is increasingly borne by low- and middle-income countries.
- Expansion of health insurance and primary health care should be accompanied with diabetes programmes that realign and resource health services to enhance the early detection and effective treatment of diabetes.

